Top 10 most-read articles of the year 2024
For the second year running, pharmaceuticals and medical devices cases dominate JUVE Patent's ten most-read articles. Top of the list is the report on highly controversial weight-loss drug Ozempic, though Bayer's seemingly never-ending global fight for rivaroxaban continues to fascinate, with two articles on the case making this year's list.
30 December 2024 by Laura King
Meanwhile, the battle over mRNA vaccines is still attracting attention four years after the outbreak of coronavirus, while glucose monitoring and heart valves are proving to be perennial topics of interest. Interestingly, none of the major mobile communications battles at the UPC has made it onto this year’s most-read. Instead, experts were interested in our report on the Nokia-Oppo settlement that never reached the UPC level. Also our report from December 2023 on Huawei’s blow against Amazon over Wifi-6 routers in Germany attracted readers in 2024.
These are the top ten most-read articles by JUVE Patent readers in 2024:
1. Generic drug companies attack Novo Nordisk’s diabetes and weight-loss drug
2. Why Bayer is fighting so hard for Xarelto
3. UK courts revoke Bayer rivaroxaban patent in new win for generics
4. Court of Appeal judges pave way back to European market for NanoString
5. What associates earn in German patent litigation practices
6. Edwards deals a severe blow to Meril with regular advisors
7. Moderna takes first win in UK trials with Pfizer and BioNTech
8. Abbott launches new wave of CGM patent lawsuits against SiBio in Europe
9. Settlement season continues as Nokia and Oppo end global patent battle
10. Huawei and Bird & Bird successful against Amazon in dispute over wifi routers
